151 related articles for article (PubMed ID: 36100836)
1. ASO Author Reflections: Challenges of Circulating Tumor DNA in the Management of Gastrointestinal Peritoneal Carcinomatosis.
Sullivan BG; Dayyani F; Senthil M
Ann Surg Oncol; 2023 Jan; 30(1):285-286. PubMed ID: 36100836
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Circulating Tumor DNA in Peritoneal Carcinomatosis.
Baumgartner JM; Kurzrock R
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):772-773. PubMed ID: 30421042
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Potential Values of Peritoneal Cell-Free Tumor DNA Testing.
Chan CHF
Ann Surg Oncol; 2020 Dec; 27(13):5072-5073. PubMed ID: 33078317
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.
Baumgartner JM; Riviere P; Kurzrock R
Ann Surg Oncol; 2020 Sep; 27(9):3268-3269. PubMed ID: 32303875
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Targeting the Immunosuppressive Tumor Microenvironment for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer.
Chan CHF
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):759-760. PubMed ID: 32451943
[No Abstract] [Full Text] [Related]
6. Peritoneal carcinomatosis of gastrointestinal tumors: where are we now?
Terzi C; Arslan NC; Canda AE
World J Gastroenterol; 2014 Oct; 20(39):14371-80. PubMed ID: 25339824
[TBL] [Abstract][Full Text] [Related]
7. ASO Author Reflections: Molecular Profiling Can Provide Personalized Clinical Guidance in the Management of Peritoneal Malignancies.
Moaven O; Miller LD; Levine EA
Ann Surg Oncol; 2020 Dec; 27(13):5024-5025. PubMed ID: 32749622
[No Abstract] [Full Text] [Related]
8. ASO Author Reflections: Treatment and Prognosis of Colorectal Peritoneal Metastases.
Bakkers C; Lurvink RJ; van Erning FN; Nienhuijs SW; de Hingh IHJT
Ann Surg Oncol; 2021 Dec; 28(13):9084-9085. PubMed ID: 34091776
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: What Is the Best Treatment for Gastric Cancer with Positive Peritoneal Lavage Cytology or Localized Peritoneum Metastasis?
Yamaguchi T; Takashima A; Boku N
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):737-738. PubMed ID: 31802300
[No Abstract] [Full Text] [Related]
10. Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations.
Miao N; Pingpank JF; Alexander HR; Royal R; Steinberg SM; Quezado MM; Beresnev T; Quezado ZM
Ann Surg Oncol; 2009 Feb; 16(2):334-44. PubMed ID: 19050961
[TBL] [Abstract][Full Text] [Related]
11. ASO Author Reflections: Prognosticating the Treatment Outcome for Primary Peritoneal Surface Malignancy: Time for an Overhaul of Scoring Systems?
Ihemelandu C
Ann Surg Oncol; 2023 Mar; 30(3):1838-1839. PubMed ID: 36629992
[No Abstract] [Full Text] [Related]
12. Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies.
Ströhlein MA; Heiss MM
J Surg Oncol; 2009 Sep; 100(4):329-30. PubMed ID: 19697440
[TBL] [Abstract][Full Text] [Related]
13. ASO Author Reflections: Postoperative Inflammatory Markers as a Surveillance Tool in Colorectal Peritoneal Carcinomatosis.
Tan JW; Thiagarajan S; Zhou S; Tan QX; Hendrikson J; Ng WH; Ng G; Liu Y; Wong JSM; Tan GHC; Soo KC; Teo MCC; Chia CS; Ong CJ
Ann Surg Oncol; 2021 Oct; 28(11):6636-6637. PubMed ID: 33733373
[No Abstract] [Full Text] [Related]
14. Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis.
McLemore EC; Pockaj BA; Reynolds C; Gray RJ; Hernandez JL; Grant CS; Donohue JH
Ann Surg Oncol; 2005 Nov; 12(11):886-94. PubMed ID: 16177864
[TBL] [Abstract][Full Text] [Related]
15. Peritoneal carcinomatosis.
Coccolini F; Gheza F; Lotti M; Virzì S; Iusco D; Ghermandi C; Melotti R; Baiocchi G; Giulini SM; Ansaloni L; Catena F
World J Gastroenterol; 2013 Nov; 19(41):6979-94. PubMed ID: 24222942
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis.
Beaujard AC; Glehen O; Caillot JL; Francois Y; Bienvenu J; Panteix G; Garbit F; Grandclément E; Vignal J; Gilly FN
Cancer; 2000 Jun; 88(11):2512-9. PubMed ID: 10861427
[TBL] [Abstract][Full Text] [Related]
17. Natural history of peritoneal carcinomatosis from nongynecologic malignancies.
Glehen O; Osinsky D; Beaujard AC; Gilly FN
Surg Oncol Clin N Am; 2003 Jul; 12(3):729-39, xiii. PubMed ID: 14567027
[TBL] [Abstract][Full Text] [Related]
18. ASO Author Reflections: Clinical Significance of Primary Tumor Side in Peritoneal Metastatic Colon Cancer.
Kotha NV; Kelly KJ
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):764-765. PubMed ID: 31602580
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: The Peritoneum is an Active Immunological Compartment.
Thorgersen EB; Flatmark K
Ann Surg Oncol; 2021 Sep; 28(9):5263-5264. PubMed ID: 33939046
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: To Redo or Not to Redo, That is the Question: Assessing the Slings and Arrows of Repeat CRS/HIPEC in Patients with Recurrent or Progressive Peritoneal Carcinomatosis.
Powers BD; Dineen SP
Ann Surg Oncol; 2020 Dec; 27(13):4892-4893. PubMed ID: 32318947
[No Abstract] [Full Text] [Related]
[Next] [New Search]
